Elevance Health (ELV) Company Report

Elevance Health has issued a policy effective October 21, 2025 covering HistoSonics’ non-invasive histotripsy system for liver tumors
Coverage applies to commercial, Medicare, and Medicaid plans in 14 states, including California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, and Wisconsin
The expansion increases access to approximately 45.4 million members
Decision is based on growing clinical evidence of long-term safety and efficacy of HistoSonics’ histotripsy therapy

Oct 22, 2025, 12:00 PM

Press Release

Elevance Health expands coverage for non-invasive liver tumor therapy

ELV

Elevance Health will extend insurance coverage for HistoSonics’ non-invasive histotripsy treatment of hepatic tumors to about 45.4 million members across its commercial, Medicare and Medicaid plans, effective October 21, 2025.
Coverage will include plans in 14 states—California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia and Wisconsin—broadening patient access to the therapy.
The decision is driven by growing clinical evidence of the long-term safety and efficacy of the Edison® Histotripsy System, with additional real-world data currently being collected worldwide.

Oct 22, 2025, 12:00 PM

Press Release

Elevance Health expands coverage for HistoSonics’ non-invasive liver tumor therapy

ELV

Product Launch

Elevance Health will extend insurance coverage for HistoSonics’ Edison® histotripsy system to 45.4 million plan members across 14 states, broadening access to non-invasive liver tumor treatment.
The Edison® system, FDA-cleared via De Novo in October 2023, uses focused ultrasound to mechanically ablate tumors without incision, radiation, or heat.
In the HOPE4LIVER pivotal trial, the system achieved 90 % tumor control at 12 months with comparable outcomes and shorter recovery versus existing ablation therapies.
Coverage decisions build on multiple Blue Cross Blue Shield plan approvals, and HistoSonics is pursuing UNOS recognition to include histotripsy in liver transplant candidate selection.

Oct 22, 2025, 12:00 PM

Press Release

Elevance Health expands insurance coverage for HistoSonics histotripsy

ELV

Effective October 21, 2025, Elevance Health will cover HistoSonics’ non-invasive histotripsy for liver tumors, extending access to 45.4 million members across 14 states.
Coverage spans commercial, Medicare and Medicaid plans in California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia and Wisconsin.
The decision is driven by growing clinical and real-world data demonstrating the safety and efficacy of histotripsy in treating liver tumors, enhancing non-invasive treatment options.

Oct 22, 2025, 12:00 PM

Press Release

Elevance Health expands non-invasive liver tumor therapy coverage

ELV

Effective October 21, 2025, Elevance Health will cover HistoSonics’ Edison® system across 14 states—including California, Texas, Florida and New York—for its commercial, Medicare and Medicaid plans, benefiting 45.4 million members.
HistoSonics’ Edison system, which received FDA De Novo authorization in October 2023, employs focused ultrasound to mechanically ablate liver tumors without incisions or heat; #HOPE4LIVER key trial data showed a 90% local tumor-control rate at 12 months.
Elevance’s decision reflects a broader trend of payer adoption of histotripsy and follows UNOS listing the system as a treatment option for patients awaiting liver transplants, underscoring growing insurer support for non-invasive oncology solutions.

Oct 22, 2025, 12:00 PM

Press Release

Elevance Health expands coverage for HistoSonics liver tumor treatment

ELV

Effective Oct. 21, 2025, Elevance Health will cover HistoSonics’ Edison® histotripsy system for non-invasive liver tumor ablation in its commercial, Medicare and Medicaid plans across 14 states.
The expansion benefits 45.4 million Elevance Health members.
HistoSonics’ histotripsy technology, FDA-authorized via De Novo in October 2023, uses focused ultrasound to mechanically disrupt and liquefy liver tumors without incisions, needles or thermal ablation.
The coverage decision aligns with growing insurer adoption and the inclusion of the system on UNOS protocols for patients awaiting liver transplantation.

Oct 22, 2025, 12:00 PM

Press Release

Elevance Health expands insurance coverage for non-invasive liver tumor treatment

ELV

Effective 21 October 2025, Elevance Health extends histotripsy coverage to 45.4 million members across commercial, Medicare and Medicaid plans.
Coverage applies in 14 states, including California, New York and Ohio.
Decision is based on increasing clinical and real-world evidence of safety and efficacy, with ongoing long-term data collection in global centers.

Oct 22, 2025, 12:00 PM

Press Release

Elevance Health expands insurance coverage for non-invasive liver tumor treatment

ELV

Effective October 21, 2025, Elevance Health will extend insurance coverage for HistoSonics’ non-invasive Edison Histotripsy System to 45.4 million members across commercial, Medicare and Medicaid plans in 14 states.
Coverage expansion is based on growing clinical evidence for safety and efficacy since the device’s FDA De Novo approval in October 2023.
The pivotal HOPE4LIVER study demonstrated a 90% local tumor control rate at 12 months, on par with existing ablation therapies, with fewer complications and faster recovery.
This decision builds on earlier coverage by multiple Blue Cross Blue Shield plans and UNOS’s adoption of histotripsy as a locoregional therapy option for liver transplant candidates.

Oct 22, 2025, 12:00 PM

Press Release

Elevance Health expands insurance coverage for histotripsy liver treatment

ELV

Effective October 21, 2025, Elevance Health issues a positive medical policy covering HistoSonics’ non-invasive histotripsy for liver tumors across its commercial, Medicare, and Medicaid plans in 14 states, expanding access to 45.4 million members.
The policy leverages mounting clinical evidence for the Edison® Histotripsy System, which earned FDA De Novo authorization in October 2023 for non-thermal liver tumor ablation.
Pivotal #HOPE4LIVER trial results show a 90% local tumor control rate at 12 months, comparable to existing ablative therapies while reducing complications and recovery time.
This expansion follows prior coverage decisions by multiple Blue Cross Blue Shield plans and complements UNOS recognition of histotripsy as an approved loco-regional therapy for patients awaiting liver transplantation.

Oct 22, 2025, 12:00 PM

Press Release

Elevance Health reports Q3 2025 results

ELV

Earnings

Guidance Update

GAAP EPS of $5.32 and adjusted EPS of $6.30, revenue of $50.1 billion (+12% YoY); ended Q3 with 45.4 million medical members and a 91.3% consolidated benefit expense ratio.
Reaffirmed FY 2025 adjusted EPS guidance of ~$30, with a $27 baseline excluding $3 of nonrecurring items.
Provided preliminary 2026 planning assumptions: anticipate at least a 125 basis point YoY decline in Medicaid margins, slight improvement in Medicare operating margin, and high single-digit decline in ACA margins under current policies.
CarillonRx revenue grew 20% YoY, Carillon services rose >50%, and Carillon external revenue expanded double digits, driven by strong organic growth and recent acquisitions.

Oct 21, 2025, 12:30 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for Elevance Health.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Gail Boudreaux say about margins?What are Elevance Health's strategic priorities?How is Elevance Health positioned vs competitors?How did Elevance Health do last quarter?

Let Fintool AI Agent track Elevance Health's earnings for you

Get instant analysis when filings drop